BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22809120)

  • 41. Glutathione S-transferase P1 gene rs4147581 polymorphism predicts overall survival of patients with hepatocellular carcinoma: evidence from an enlarged study.
    Wang Z; Qu K; Niu W; Lin T; Xu X; Huang Z; Liu S; Liu S; Chang H; Liu Y; Dong X; Liu C; Zhang Y
    Tumour Biol; 2016 Jan; 37(1):943-52. PubMed ID: 26260272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.
    Cabibbo G; Genco C; Di Marco V; Barbara M; Enea M; Parisi P; Brancatelli G; Romano P; Craxì A; Cammà C
    Aliment Pharmacol Ther; 2011 Jul; 34(2):196-204. PubMed ID: 21564144
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
    Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
    J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
    Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus.
    Peng BG; He Q; Li JP; Zhou F
    Am J Surg; 2009 Sep; 198(3):313-8. PubMed ID: 19285298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Park KW; Park JW; Choi JI; Kim TH; Kim SH; Park HS; Lee WJ; Park SJ; Hong EK; Kim CM
    J Gastroenterol Hepatol; 2008 Mar; 23(3):467-73. PubMed ID: 17764529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age.
    Tseng CS; Tang KS; Lo HW; Ker CG; Teng HC; Huang CS
    Am J Gastroenterol; 2005 Aug; 100(8):1758-63. PubMed ID: 16086712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients.
    Zhang H; Guo X; Dai J; Wu Y; Ge N; Yang Y; Ji J; Zhang H
    Med Oncol; 2014 Nov; 31(11):278. PubMed ID: 25355558
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Hiraoka A; Horiike N; Yamashita Y; Koizumi Y; Doi H; Yamamoto Y; Ichikawa S; Hasebe A; Yano M; Miyamoto Y; Ninomiya T; Ootani H; Takamura K; Kawasaki H; Otomi Y; Kogame M; Sogabe I; Ishimaru Y; Kashihara K; Miyagawa M; Hirooka M; Hiasa Y; Matsuura B; Michitaka K; Onji M
    Hepatogastroenterology; 2009; 56(89):213-7. PubMed ID: 19453060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma].
    Zhang Z; Wu M; Liu Q
    Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):214-6. PubMed ID: 11776840
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
    Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
    Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic polymorphisms in circadian negative feedback regulation genes predict overall survival and response to chemotherapy in gastric cancer patients.
    Qu F; Qiao Q; Wang N; Ji G; Zhao H; He L; Wang H; Bao G
    Sci Rep; 2016 Mar; 6():22424. PubMed ID: 26927666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy.
    Hu W; Huang S; Dong L; Yu C; Li C; Zhang J
    Anticancer Drugs; 2019 Mar; 30(3):233-240. PubMed ID: 30779721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population.
    Ezzikouri S; El Feydi AE; Benazzouz M; Afifi R; El Kihal L; Hassar M; Akil A; Pineau P; Benjelloun S
    Infect Genet Evol; 2009 Sep; 9(5):877-81. PubMed ID: 19465161
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estrogen receptor alpha polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers.
    Zhai Y; Zhou G; Deng G; Xie W; Dong X; Zhang X; Yu L; Yang H; Yuan X; Zhang H; Zhi L; Yao Z; Shen Y; Qiang B; He F
    Gastroenterology; 2006 Jun; 130(7):2001-9. PubMed ID: 16762623
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus.
    Peng ZW; Guo RP; Zhang YJ; Lin XJ; Chen MS; Lau WY
    Cancer; 2012 Oct; 118(19):4725-36. PubMed ID: 22359112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemoembolization in patients at high risk: results and complications.
    Kiely JM; Rilling WS; Touzios JG; Hieb RA; Franco J; Saeian K; Quebbeman EJ; Pitt HA
    J Vasc Interv Radiol; 2006 Jan; 17(1):47-53. PubMed ID: 16415132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma.
    Giannini EG; Bodini G; Corbo M; Savarino V; Risso D; Di Nolfo MA; Del Poggio P; Benvegnù L; Farinati F; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
    Aliment Pharmacol Ther; 2010 Feb; 31(4):493-501. PubMed ID: 19912152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
    Sergio A; Cristofori C; Cardin R; Pivetta G; Ragazzi R; Baldan A; Girardi L; Cillo U; Burra P; Giacomin A; Farinati F
    Am J Gastroenterol; 2008 Apr; 103(4):914-21. PubMed ID: 18177453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.